IDEMIA
22.6.2020 10:02:06 CEST | Business Wire | Press release
IDEMIA today announced that its MorphoWave TM contactless fingerprint technology outperformed all other devices in the National Institute of Standards and Technology (NIST)’s latest Accuracy and Interoperability Test on all criteria involved.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200622005215/en/
The primary reason for carrying out the “Interoperability Assessment 2019: Contactless-to-Contact Fingerprint Capture ” study was to test how well touchless systems work with legacy databases. NIST tested six sold contactless fingerprint scanning technologies by comparing how they fared with conventional touch-based fingerprint devices. The results show that contactless devices that scanned multiple fingers consistently achieved better accuracy than single finger scanning and made less “false positive” errors that incorrectly matched a person’s print with someone else’s.
MorphoWave TM is a stand-out IDEMIA-developed technology that scans and checks four fingerprints in under a second by just waiving your hand within the reader. Shown as Dev03 in the report, MorphoWave TM consistently performs better than other contactless devices in terms of matching rate, image capture sample rate, areas of overlap between probe and exemplar fingerprints, finger ridges and minutiae similarity. Further testing was conducted with both contact and contactless probes matched to the MorphoWave TM exemplar contactless fingerprints.
This testing confirms MorphoWave TM , which already underpins the currently sold MorphoWave TM Compact, works well with legacy touch fingerprint scanners and other contactless solutions alike. It also highlights that this technology enables extremely efficient contactless fingerprint capture and matching against existing contact-based fingerprint databases. This latter feature is very beneficial for some government programs, border checks and minimizing passenger lines whenever user fingerprints are already held in a database. So MorphoWave TM gives passengers a smoother and more hygienic user experience.
IDEMIA CTO Jean-Christophe Fondeur said: “The recent COVID19 pandemic has ushered in growing demand for contactless and hygienic solutions. We are delighted to see contactless fingerprint capture that we pioneered is on the cusp of matching contact-based accuracy, and of course that our MorphoWave TM technology has emerged from this NIST interoperability test as the best in the industry. Given its outstanding capacity as borne out by this NIST test, our MorphoWave TM Compact is a game changer and will seamlessly raise hygiene standards in a vast array of environments including corporate offices, stores, airports, theme parks and leisure and entertainment venues.”
About NIST :
Founded in 1901, NIST is a non-regulatory federal agency within the U.S. Department of Commerce. NIST's mission is to promote U.S. innovation and industrial competitiveness by advancing measurement science, standards, and technology in ways that enhance economic security and improve our quality of life.
From smart electric power grid and electronic health records to atomic clocks, advanced nanomaterials and computer chips, innumerable products and services rely in some way on technology, measurement, and standards provided by the National Institute of Standards and Technology.
Link to Interoperability Assessment 2019: Contactless-to-Contact Fingerprint Capture study: https://nvlpubs.nist.gov/nistpubs/ir/2020/NIST.IR.8307.pdf
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20200622005215/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lattice to Showcase Industrial FPGA Innovations at FPGAWorld Conference 202625.8.2026 22:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced its exhibition plan for the upcoming FPGAWorld Conference 2026, taking place on Sept. 8, 2026, in Stockholm, Sweden. As part of the event, Lattice will deliver technical presentations and host a demo showcase focused on how its low power FPGA solutions are advancing Industrial IoT and sensor bridging applications. Who: Lattice Semiconductor What / When (GMT+2): Tuesday, Sept. 8, 2026 Lattice Demo Showcase Presentations (Track: 12:20 – 13:35, Room Brave 05) “Solving Your Power Puzzle: Lattice FPGAs’ Path to Uncompromised Low Power” “Practical Security Fundamentals for FPGA Engineers” Where: AFRY, Frösundaleden 2A, 169 70 Solna, Sweden The FPGAWorld Conference is an international forum for researchers, engineers, teachers, students, and hackers. It covers topics such as complex analog/digital/software FPGA SoC systems, FPGA/ASIC-based products, educational and industrial cases,
France Becomes First Official Participant at Expo 2030 Riyadh25.8.2026 19:40:00 CEST | Press release
France is the first country to officially sign its Participation Contract for Expo 2030 Riyadh, a major milestone in its preparations and growing international momentum. The signing took place on the sidelines of the visit to France by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825634516/en/ The ceremony in Paris was attended by H.H. Prince Faisal bin Farhan Al Saud, Minister of Foreign Affairs of the Kingdom of Saudi Arabia, and Dimitri S. Kerkentzes, Secretary General of the BIE. The Participation Contract was signed by Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh, and Jacques Maire, Chairman of the Compagnie Française des Expositions (COFREX). The agreement formally establishes France’s participation in Expo 2030 Riyadh, providing the framework for its presence throughout the six-month event. It spec
Saudi Arabia and BIE Sign See Agreement for Expo 2030 Riyadh, Advancing Framework for International Participation25.8.2026 19:17:00 CEST | Press release
The Kingdom of Saudi Arabia and the Bureau International des Expositions (BIE) have signed the See Agreement for Expo 2030 Riyadh, formally establishing the legal and administrative framework that will support Official Participants throughout their journey to the World Expo. The signing took place on the sidelines of the visit to France by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825419959/en/ H.H. Prince Faisal bin Farhan Al Saud, Minister of Foreign Affairs of the Kingdom of Saudi Arabia, and Dimitri S. Kerkentzes, Secretary General of the BIE, at the ceremony. The ceremony was attended by H.H. Prince Faisal bin Farhan Al Saud, Minister of Foreign Affairs of the Kingdom of Saudi Arabia, Dimitri S. Kerkentzes, Secretary General of the BIE, and Talal Al-Marri, CEO of Expo 2030 Riyadh. The See Agreement sets out the
The LYCRA Company Reimagines the Trade Show Experience at Intertextile25.8.2026 18:11:00 CEST | Press release
Immersive Co-Creation District Showcases New Fiber Innovations and Value Chain Collaboration The LYCRA Company, a global leader in fiber and technology solutions for the apparel industry, is reimagining the trade show experience at Intertextile Shanghai Apparel Fabrics Autumn Edition, which opened today in China. Building on the success of last year's ALL IN concept, the company has expanded its co-creation vision into a 356-square-meter Lifestyle District featuring partners Jingzili New Material, JYT Textile, Lianxingfa Knitting, and Trend Textile. The district is part of a larger 895-square-meter pavilion showcasing a total of 19 co-exhibitors. Together, they demonstrate how innovations in fiber, fabric, and garments can be combined to create compelling solutions for both work and play. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260821281698/en/ The LYCRA Company expands its co-creation vision through an immersive Life
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA25.8.2026 16:40:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ GEA, regardless of PD-L1 statusRegimen poised to become standard of care in this difficult-to-treat disease. BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). The approval is supported by results from the Phase 3 HERIZON-GEA-01 trial, which were published in The New England Journal of Medicine earlier this year. GEA, which includes adenocarcinomas of the stomach, gastroesophageal junction and e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
